

- (a) a nucleic acid encoding a protein having an amino acid sequence as represented in any of SEQ ID NOS 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 418, 420, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, or 484, or encoding a functional equivalent, derivative or bioprecursor of said protein;
- (b) a nucleic acid molecule encoding a protein having an amino acid sequence which is more than 70% similar, preferably more than 80% similar, more preferably more than 90%

similar and most preferably more than 97% similar to any of the amino acid sequences shown in SEQ ID NOS 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 418, 420, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, or 484;

- (c) a nucleic acid molecule encoding a protein having an amino acid sequence which is more than 70% identical, preferably more than 80% identical, more preferably more than 90% identical and most preferably more than 97%

identical to any of the amino acid sequences shown in SEQ ID NOS 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 418, 420, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, or 484;

- (d) a nucleic acid molecule comprising a sequence as represented in any of SEQ ID NOS 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91,

93, 95, 97, 99, 101, 103, 105, 107, 109, 111,  
113, 115, 117, 119, 121, 123, 125, 127, 129,  
131, 133, 135, 137, 139, 141, 143, 145, 147,  
149, 151, 153, 155, 157, 159, 161, 163, 165,  
167, 169, 171, 173, 175, 177, 179, 181, 183,  
185, 187, 189, 191, 193, 195, 197, 199, 201,  
203, 205, 207, 209, 211, 213, 215, 217, 219,  
221, 223, 225, 227, 229, 231, 233, 235, 237,  
239, 241, 243, 245, 247, 249, 251, 253, 255,  
257, 259, 261, 263, 265, 267, 269, 271, 273,  
275, 277, 279, 281, 283, 285, 287, 289, 291,  
293, 295, 297, 299, 301, 303, 305, 307, 309,  
311, 313, 315, 317, 319, 321, 323, 325, 327,  
329, 331, 333, 335, 337, 339, 341, 343, 345,  
347, 349, 351, 353, 355, 357, 359, 361, 363,  
365, 367, 369, 371, 373, 375, 377, 379, 381,  
383, 385, 387, 389, 391, 393, 395, 397, 399,  
401, 403, 405, 407, 409, 411, 413, 415, 417,  
419, 421, 423, 425, 427, 429, 431, 433, 435,  
437, 439, 441, 443, 445, 447, 449, 451, 453,  
455, 457, 459, 461, 463, 465, 467, 469, 471,  
473, 475, 477, 479, 481 or 483;

- (e) a nucleic acid sequence which is more than 70% identical, preferably more than 80% identical, more preferably more than 90% identical and most preferably more than 97% identical to any of the nucleic acid sequences shown in SEQ ID NOs 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139,

141, 143, 145, 147, 149, 151, 153, 155, 157,  
 159, 161, 163, 165, 167, 169, 171, 173, 175,  
 177, 179, 181, 183, 185, 187, 189, 191, 193,  
 195, 197, 199, 201, 203, 205, 207, 209, 211,  
 213, 215, 217, 219, 221, 223, 225, 227, 229,  
 231, 233, 235, 237, 239, 241, 243, 245, 247,  
 249, 251, 253, 255, 257, 259, 261, 263, 265,  
 267, 269, 271, 273, 275, 277, 279, 281, 283,  
 285, 287, 289, 291, 293, 295, 297, 299, 301,  
 303, 305, 307, 309, 311, 313, 315, 317, 319,  
 321, 323, 325, 327, 329, 331, 333, 335, 337,  
 339, 341, 343, 345, 347, 349, 351, 353, 355,  
 357, 359, 361, 363, 365, 367, 369, 371, 373,  
 375, 377, 379, 381, 383, 385, 387, 389, 391,  
 393, 395, 397, 399, 401, 403, 405, 407, 409,  
 411, 413, 415, 417, 419, 421, 423, 425, 427,  
 429, 431, 433, 435, 437, 439, 441, 443, 445,  
 447, 449, 451, 453, 455, 457, 459, 461, 463,  
 465, 467, 469, 471, 473, 475, 477, 479, 481 or  
 483; [and]

(f) or the functional fragment or complement  
 thereof

for the preparation of a medicament for treating  
 diseases associated with yeast or fungi.

2. (Amended) An isolated polypeptide which is  
 involved in a pathway leading to programmed cell death  
 of yeast or fungi, said polypeptide being selected  
 from :

(a) a protein having an amino acid sequence as  
 represented in any of SEQ ID NOs 2, 4, 6, 8,  
 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30,  
 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52,  
 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74,

76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96,  
98, 100, 102, 104, 106, 108, 110, 112, 114,  
116, 118, 120, 122, 124, 126, 128, 130, 132,  
134, 136, 138, 140, 142, 144, 146, 148, 150,  
152, 154, 156, 158, 160, 162, 164, 166, 168,  
170, 172, 174, 176, 178, 180, 182, 184, 186,  
188, 190, 192, 194, 196, 198, 200, 202, 204,  
206, 208, 210, 212, 214, 216, 218, 220, 222,  
224, 226, 228, 230, 232, 234, 236, 238, 240,  
242, 244, 246, 248, 250, 252, 254, 256, 258,  
260, 262, 264, 266, 268, 270, 272, 274, 276,  
278, 280, 282, 284, 286, 288, 290, 292, 294,  
296, 298, 300, 302, 304, 306, 308, 310, 312,  
314, 316, 318, 320, 322, 324, 326, 328, 330,  
332, 334, 336, 338, 340, 342, 344, 346, 348,  
350, 352, 354, 356, 358, 360, 362, 364, 366,  
368, 370, 372, 374, 376, 378, 380, 382, 384,  
386, 388, 390, 392, 394, 396, 398, 400, 402,  
404, 406, 408, 410, 412, 414, 416, 418, 420,  
422, 424, 426, 428, 430, 432, 434, 436, 438,  
440, 442, 444, 446, 448, 450, 452, 454, 456,  
458, 460, 462, 464, 466, 468, 470, 472, 474,  
476, 478, 480, 482, or 484, or encoding a  
functional equivalent, derivative or  
bioprecursor of said protein;

- (b) a protein having an amino acid sequence  
which is more than 70% similar, preferably  
more than 80% similar, more preferably more  
than 90% similar and most preferably more than  
97% similar to any of the amino acid sequences  
shown in SEQ ID NOs 2, 4, 6, 8, 10, 12, 14,  
16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36,  
38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58,  
60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80,

82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102,  
104, 106, 108, 110, 112, 114, 116, 118, 120,  
122, 124, 126, 128, 130, 132, 134, 136, 138,  
140, 142, 144, 146, 148, 150, 152, 154, 156,  
158, 160, 162, 164, 166, 168, 170, 172, 174,  
176, 178, 180, 182, 184, 186, 188, 190, 192,  
194, 196, 198, 200, 202, 204, 206, 208, 210,  
212, 214, 216, 218, 220, 222, 224, 226, 228,  
230, 232, 234, 236, 238, 240, 242, 244, 246,  
248, 250, 252, 254, 256, 258, 260, 262, 264,  
266, 268, 270, 272, 274, 276, 278, 280, 282,  
284, 286, 288, 290, 292, 294, 296, 298, 300,  
302, 304, 306, 308, 310, 312, 314, 316, 318,  
320, 322, 324, 326, 328, 330, 332, 334, 336,  
338, 340, 342, 344, 346, 348, 350, 352, 354,  
356, 358, 360, 362, 364, 366, 368, 370, 372,  
374, 376, 378, 380, 382, 384, 386, 388, 390,  
392, 394, 396, 398, 400, 402, 404, 406, 408,  
410, 412, 414, 416, 418, 420, 422, 424, 426,  
428, 430, 432, 434, 436, 438, 440, 442, 444,  
446, 448, 450, 452, 454, 456, 458, 460, 462,  
464, 466, 468, 470, 472, 474, 476, 478, 480,  
482, or 484;

- (c) a protein having an amino acid sequence which is more than 70% identical, preferably more than 80% identical, more preferably more than 90% identical and most preferably more than 97% identical to any of the amino acid sequences shown in SEQ ID NOs 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116,

118, 120, 122, 124, 126, 128, 130, 132, 134,  
136, 138, 140, 142, 144, 146, 148, 150, 152,  
154, 156, 158, 160, 162, 164, 166, 168, 170,  
172, 174, 176, 178, 180, 182, 184, 186, 188,  
190, 192, 194, 196, 198, 200, 202, 204, 206,  
208, 210, 212, 214, 216, 218, 220, 222, 224,  
226, 228, 230, 232, 234, 236, 238, 240, 242,  
244, 246, 248, 250, 252, 254, 256, 258, 260,  
262, 264, 266, 268, 270, 272, 274, 276, 278,  
280, 282, 284, 286, 288, 290, 292, 294, 296,  
298, 300, 302, 304, 306, 308, 310, 312, 314,  
316, 318, 320, 322, 324, 326, 328, 330, 332,  
334, 336, 338, 340, 342, 344, 346, 348, 350,  
352, 354, 356, 358, 360, 362, 364, 366, 368,  
370, 372, 374, 376, 378, 380, 382, 384, 386,  
388, 390, 392, 394, 396, 398, 400, 402, 404,  
406, 408, 410, 412, 414, 416, 418, 420, 422,  
424, 426, 428, 430, 432, 434, 436, 438, 440,  
442, 444, 446, 448, 450, 452, 454, 456, 458,  
460, 462, 464, 466, 468, 470, 472, 474, 476,  
478, 480, 482, or 484; or a functional  
fragment thereof

for the preparation of a medicament for treating  
diseases associated with yeast or fungi.

10. (Amended) A yeast or fungus comprising the nucleic  
acid of claim 1 wherein the yeast or fungus is  
selected from the group consisting of  
*Saccharomyces cerevisiae*, *Schizosaccharomyces*  
*pombe*, *Candida albicans*, or *Aspergillus fumigatus*.

11. (Amended) A compound identifiable according to the  
method of claim 6.

12. (Amended) A medicament comprising the compound according to claim 11.

13. (Amended) A method for preparing a pharmaceutical composition for treating diseases associated with yeast or fungi comprising admixing a medicament according to claim 12 with a suitable pharmaceutically acceptable carrier.

14. (Amended) A method for treating a yeast or fungal infection in a subject comprising the step of administering a compound according to claim 11.

15. (Amended) A method for modifying the endogenic flora of humans and other mammals comprising the step of administering a compound according to claim 11.

16. (Amended) The method of claim 14 wherein the yeast or fungal infection is an infection caused by the yeast or fungi selected from the group consisting of *Candida* spp., *Aspergillus* spp., *Microsporum* spp., *Trichophyton* spp., *Fusarium* spp., *Zygomycetes* spp., *Botritis*, spp., *Cladosporium* spp., *Malassezia* spp., *Epidermophyton floccosum*, *Blastomyces dermatitidis*, *Coccidioides immitis*, *Histoplasma capsulatum*, *Paracoccidioides brasiliensis*, *Cryptococcus neoformans*, and *Sporothrix schenckii*.

17. (Amended) A nucleic acid sequence encoding a polypeptide which is involved in a pathway for programmed cell death of yeast or fungi selected from:

- (a) a nucleic acid encoding a protein having an amino acid sequence as represented in any of SEQ ID NOs 286, 288, 290, 292, 296, 298, 300, 302, 304, 306, 308, 310, 312, 316, 318, 320, 322, 324, 326, 328, 330, 332, 338, 342, 344, 346, 348, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 380, 382, 384, 386, 388, 390, 392, 394, 398, 402, 404, 406, 408, 410, 412, 416, 418, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 476, 478, 480, 482 or 484, or encoding a functional equivalent, derivative or bioprecursor of said protein;
- (b) a nucleic acid molecule encoding a protein having an amino acid sequence which is more than 70% similar, preferably more than 80% similar, more preferably more than 90% similar and most preferably more than 97% similar to any of the amino acid sequences shown in SEQ ID NOs 286, 288, 290, 292, 296, 298, 300, 302, 304, 306, 308, 310, 312, 316, 318, 320, 322, 324, 326, 328, 330, 332, 338, 342, 344, 346, 348, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 380, 382, 384, 386, 388, 390, 392, 394, 398, 402, 404, 406, 408, 410, 412, 416, 418, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 476, 478, 480, 482 or 484;
- (c) a nucleic acid molecule encoding a protein having an amino acid sequence which is more than 70% identical, preferably more than 80% identical, more preferably more than 90% identical and most preferably more than 97% identical to any of the amino acid sequences shown in SEQ ID NOs 286, 288, 290, 292, 296, 298, 300, 302, 304, 306, 308, 310, 312, 316, 318, 320,

322, 324, 326, 328, 330, 332, 338, 342, 344, 346,  
348, 352, 354, 356, 358, 360, 362, 364, 366, 368,  
370, 372, 374, 376, 380, 382, 384, 386, 388, 390,  
392, 394, 398, 402, 404, 406, 408, 410, 412, 416,  
418, 422, 424, 426, 428, 430, 432, 434, 436, 438,  
440, 442, 444, 446, 448, 450, 452, 454, 476, 478,  
480, 482 or 484;

(d) a nucleic acid molecule comprising a sequence as represented in any of SEQ ID NOs 285, 287, 289, 291, 295, 297, 299, 301, 303, 305, 307, 309, 311, 315, 317, 319, 321, 323, 325, 327, 329, 331, 337, 341, 343, 345, 347, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 379, 381, 383, 385, 387, 389, 391, 393, 397, 401, 403, 405, 407, 409, 411, 415, 417, 421, 423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 475, 477, 479, 481 or 483;

(e) a nucleic acid sequence which is more than 70% identical, preferably more than 80% identical, more preferably more than 90% identical and most preferably more than 97% identical to any of the nucleic acid sequences shown in SEQ ID NOs 285, 287, 289, 291, 295, 297, 299, 301, 303, 305, 307, 309, 311, 315, 317, 319, 321, 323, 325, 327, 329, 331, 337, 341, 343, 345, 347, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 379, 381, 383, 385, 387, 389, 391, 393, 397, 401, 403, 405, 407, 409, 411, 415, 417, 421, 423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 475, 477, 479, 481 or 483; or a functional fragment or complement thereof.

18. (Amended) A nucleic acid according to claim 16 wherein the nucleic acid is derived from *Candida albicans*.

20. (Amended) A nucleic acid sequence according to claim 17 which is mRNA.

21. (Amended) A nucleic acid sequence according to claim 17 which is DNA.

22. (Amended) A nucleic acid sequence according to claim 17 which is cDNA.

23. (Amended) An antisense molecule comprising a nucleic acid sequence capable of selectively hybridizing to the nucleic acid sequences according to claim 17.

24. (Amended) An isolated protein which is involved in a pathway for programmed cell death of yeast or fungi selected from:

- (a) a protein having an amino acid sequence as represented in any of SEQ ID NOs 286, 288, 290, 292, 296, 298, 300, 302, 304, 306, 308, 310, 312, 316, 318, 320, 322, 324, 326, 328, 330, 332, 338, 342, 344, 346, 348, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 380, 382, 384, 386, 388, 390, 392, 394, 398, 402, 404, 406, 408, 410, 412, 416, 418, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 476, 478, 480, 482 or 484, or encoding a functional equivalent, derivative or bioprecursor of said protein;

(b) a protein having an amino acid sequence which is more than 70% similar, preferably more than 80% similar, more preferably more than 90% similar and most preferably more than 97% similar to any of the amino acid sequences shown in SEQ ID NOs 286, 288, 290, 292, 296, 298, 300, 302, 304, 306, 308, 310, 312, 316, 318, 320, 322, 324, 326, 328, 330, 332, 338, 342, 344, 346, 348, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 380, 382, 384, 386, 388, 390, 392, 394, 398, 402, 404, 406, 408, 410, 412, 416, 418, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 476, 478, 480, 482 or 484;

(a) a protein having an amino acid sequence which is more than 70% identical, preferably more than 80% identical, more preferably more than 90% identical and most preferably more than 97% identical to any of the amino acid sequences shown in SEQ ID NOs 286, 288, 290, 292, 296, 298, 300, 302, 304, 306, 308, 310, 312, 316, 318, 320, 322, 324, 326, 328, 330, 332, 338, 342, 344, 346, 348, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 380, 382, 384, 386, 388, 390, 392, 394, 398, 402, 404, 406, 408, 410, 412, 416, 418, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 476, 478, 480, 482 or 484; or a functional fragment thereof.

25. (Amended) An expression vector comprising a nucleic acid sequence according to claim 17.

27. (Amended) An expression vector according to claim 25 which comprises a sequence encoding a reporter molecule.
28. (Amended) A host cell transformed, transfected or infected with the vector of claim 25.
29. (Amended) A nucleic acid molecule according to claim 17 for use as a medicament.
33. (Amended) A pharmaceutical composition comprising an antibody according to claim 31.
34. (Amended) A method for treating a yeast or fungal infection comprising the step of administering an antibody according to claim 31, or an antibody capable of binding to at least one of the polypeptides as defined in claim 2.
35. (Amended) The method of claim 34 wherein the fungus is *Candida albicans*.
36. (Amended) A nucleic acid probe which comprises a fragment of at least 15 contiguous nucleotides of a nucleic acid molecule as defined in claim 17 wherein the nucleic acid probe selectively hybridises with the nucleic acid molecule.
37. (Amended) A nucleic acid primer which comprises a fragment of at least 15 contiguous nucleotides of a nucleic acid molecule as defined in claim 17 wherein the nucleic acid primer selectively amplifies any of said nucleic acid molecules.

38. (Amended) A genetically modified mammalian cell or non-human organism in which modification results in the overexpression or underexpression of at least one of the nucleic acids of claim 1 or a human homologue thereof or at least one of the polypeptides of claim 2 or a human homologue thereof, which overexpression or underexpression of said nucleic acid or polypeptide prevents or delays apoptosis of said genetically modified mammalian cell or in said genetically modified non-human organism.

39. (Amended) A method for identifying compounds for stimulating or inhibiting apoptosis comprising the use of at least one of the nucleic acid sequences of claim 1 or a human homologue thereof and/or at least one of the polypeptides of claim 2 or a human homologue thereof and/or a genetically modified mammalian cell or non-human organism according to claim 38.

41. (Amended) A medicament comprising the compound according to claim 40.

42. (Amended) A method for preparing a pharmaceutical composition for treating proliferative disorders or for preventing apoptosis in certain diseases comprising admixing a compound according to claim 40 with a suitable pharmaceutically acceptable carrier.

43. (Amended) A method for for treating proliferative disorders or for preventing apoptosis in comprising administering the compound of claim 40 to a subject in need thereof.

44. (Amended) A method for treating proliferative disorders or for the prevention of apoptosis comprising administering a nucleic acid molecule of claim 1 to a subject in need thereof.

45. (Amended) A method for treating proliferative disorders or for the prevention of apoptosis comprising administering a polypeptide of claim 2 to a subject in need thereof.

46. (Amended) A pharmaceutical composition comprising a nucleic acid molecule as defined in claim 1 or a human homologue thereof or a polypeptide as defined in claim 2 or a human homologue thereof together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

47. (Amended) A vaccine for immunizing mammals against proliferative disorders or for preventing apoptosis comprising least one nucleic acid molecule as defined in claim 1 or a human homologue thereof or at least one polypeptide as defined in claim 2 or a human analogue thereof in a pharmaceutically acceptable carrier.

51. (Amended) An expression vector according to claim 49 which comprises a sequence encoding a reporter molecule.

52. (Amended) A host cell transformed, transfected or infected with the vector of claim 49.